Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aura Biosciences Inc AURA

Healthcare Biotechnology
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the... see more

Recent & Breaking News (NDAQ:AURA)

Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 26, 2024

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 12, 2024

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

GlobeNewswire October 17, 2024

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

GlobeNewswire September 12, 2024

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

GlobeNewswire September 3, 2024

Aura Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

GlobeNewswire August 26, 2024

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 8, 2024

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Aura Biosciences to Host Virtual KOL Event "Pioneering a New Standard of Care In Ocular Oncology" on May 29, 2024

GlobeNewswire May 23, 2024

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire May 9, 2024

Aura Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire May 8, 2024

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Business Wire March 27, 2024

Aura Biosciences to Participate in Upcoming Investor Conferences

Business Wire February 26, 2024

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Business Wire December 7, 2023

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Business Wire November 9, 2023

Aura Biosciences to Participate in Upcoming Investor Conferences

Business Wire November 8, 2023

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Business Wire November 6, 2023

Aura Biosciences Announces Proposed Public Offering of Common Stock

Business Wire November 6, 2023

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Business Wire November 6, 2023